Skip to main content
. Author manuscript; available in PMC: 2011 Jan 12.
Published in final edited form as: Mol Cancer Res. 2010 Jan 12;8(1):80–92. doi: 10.1158/1541-7786.MCR-08-0344

Figure 3.

Figure 3

STAT2 deficient H123 cells can respond to type I IFNs and remain susceptible to other death agonists. Parental and IFN resistant H123 cells were left untreated or treated with 3,000 U/ml IFN-α for the indicated times. Whole cell extracts were prepared and analyzed by Western blot analysis for (A) pY (701) STAT1 or (B) IRF-1. Membranes were reprobed for total STAT1 or Actin respectively to assess equal protein loading. The ratio of IRF-1 to Actin was quantified. C) Cells were labeled with isotype control or anti-MHC class-I (A, B and C) FITC labeled antibody and analyzed by flow cytometry. D) Parental and IFN resistant H123 cells were left untreated or treated with 1μg/ml of Trail and dually labeled with Annexin V and PI.